Litcius/Paper detail

Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study

Kelly G. Paulson, Sally C. M. Lau, Myung‐Ju Ahn, Mor Moskovitz, Michael Pogorzelski, Simon Häfliger, Amanda Parkes, Yuyang Zhang, Ali Hamidi, Corbin G. Thompson, Martin Wermke

2025The Lancet Oncology25 citationsDOI

Topics & Concepts

MedicineMaintenance therapyInternal medicineOncologyLung cancerCancerPhases of clinical researchPhase (matter)Clinical trialLungRadiation therapyChemotherapySurgeryIntensive care medicineAdverse effectAntibody therapyCancer therapyLung Cancer Research StudiesCancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study | Litcius